The Mayo Clinic Experience with the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab

Michael W. Ruff, Michelle M Mauermann

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neurological complications are an increasingly recognized complication of the use of the immune checkpoint inhibitors in the treatment of solid tumors. Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, an immune checkpoint inhibitor that suppresses T-cell effector function. The clinical spectrum of ipilimumab-associated neurological complications and optimum treatment approach is not established. We describe our institution's experience with ipilimumab and illustrate 2 cases of presumed autoimmune neurological phenomenon resulting from its use.

Original languageEnglish (US)
Pages (from-to)98-99
Number of pages2
JournalNeurologist
Volume23
Issue number3
DOIs
StatePublished - Jan 1 2018

Fingerprint

CTLA-4 Antigen
Monoclonal Antibodies
T-Lymphocytes
ipilimumab
Neoplasms

Keywords

  • checkpoint inhibitors
  • CTLA-4
  • general neurology
  • ipilimumab
  • neurological complications

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The Mayo Clinic Experience with the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab. / Ruff, Michael W.; Mauermann, Michelle M.

In: Neurologist, Vol. 23, No. 3, 01.01.2018, p. 98-99.

Research output: Contribution to journalArticle

@article{7c900d8e6b5d4ee580f1feb53fa18d17,
title = "The Mayo Clinic Experience with the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab",
abstract = "Neurological complications are an increasingly recognized complication of the use of the immune checkpoint inhibitors in the treatment of solid tumors. Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, an immune checkpoint inhibitor that suppresses T-cell effector function. The clinical spectrum of ipilimumab-associated neurological complications and optimum treatment approach is not established. We describe our institution's experience with ipilimumab and illustrate 2 cases of presumed autoimmune neurological phenomenon resulting from its use.",
keywords = "checkpoint inhibitors, CTLA-4, general neurology, ipilimumab, neurological complications",
author = "Ruff, {Michael W.} and Mauermann, {Michelle M}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/NRL.0000000000000176",
language = "English (US)",
volume = "23",
pages = "98--99",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The Mayo Clinic Experience with the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab

AU - Ruff, Michael W.

AU - Mauermann, Michelle M

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Neurological complications are an increasingly recognized complication of the use of the immune checkpoint inhibitors in the treatment of solid tumors. Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, an immune checkpoint inhibitor that suppresses T-cell effector function. The clinical spectrum of ipilimumab-associated neurological complications and optimum treatment approach is not established. We describe our institution's experience with ipilimumab and illustrate 2 cases of presumed autoimmune neurological phenomenon resulting from its use.

AB - Neurological complications are an increasingly recognized complication of the use of the immune checkpoint inhibitors in the treatment of solid tumors. Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, an immune checkpoint inhibitor that suppresses T-cell effector function. The clinical spectrum of ipilimumab-associated neurological complications and optimum treatment approach is not established. We describe our institution's experience with ipilimumab and illustrate 2 cases of presumed autoimmune neurological phenomenon resulting from its use.

KW - checkpoint inhibitors

KW - CTLA-4

KW - general neurology

KW - ipilimumab

KW - neurological complications

UR - http://www.scopus.com/inward/record.url?scp=85046949810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046949810&partnerID=8YFLogxK

U2 - 10.1097/NRL.0000000000000176

DO - 10.1097/NRL.0000000000000176

M3 - Article

C2 - 29722744

AN - SCOPUS:85046949810

VL - 23

SP - 98

EP - 99

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 3

ER -